Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Jill Kolesar; Wei Huang; Jens Eickhoff; Kristine Hahn; Dona Alberti; Steven Attia; William Schelman; Kyle Holen; Anne Traynor; Percy Ivy; George Wilding

doi:10.1007/s00280-008-0845-0

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Jill Kolesar
, Wei Huang
, Jens Eickhoff
, Kristine Hahn
, Dona Alberti
, Steven Attia
, William Schelman
, Kyle Holen
, Anne Traynor
, Percy Ivy
, George Wilding

Producción científica: Article › revisión exhaustiva

17 Citas (Scopus)

Resumen

Purpose: The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Methods: Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). Results: Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). Conclusion: RRM2 gene and protein expression varies by tumor type.

Idioma original	English
Páginas (desde-hasta)	79-86
Número de páginas	8
Publicación	Cancer Chemotherapy and Pharmacology
Volumen	64
N.º	1
DOI	https://doi.org/10.1007/s00280-008-0845-0
Estado	Published - jun 2009

Nota bibliográfica

Funding Information:
Acknowledgments Supported by: U01CA062491 “Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis” NCI; CTEP Translational Research Initiative Funding 24XS090, and 1ULRR025011. Clinical and Translational Science Award of the National Center for Research Resources, NIH; and NIH grant T32 CA009614. Physician Scientist Training in Cancer Medicine (Dr. Attia).

Financiación

Acknowledgments Supported by: U01CA062491 “Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis” NCI; CTEP Translational Research Initiative Funding 24XS090, and 1ULRR025011. Clinical and Translational Science Award of the National Center for Research Resources, NIH; and NIH grant T32 CA009614. Physician Scientist Training in Cancer Medicine (Dr. Attia).

Financiadores	Número del financiador
National Institutes of Health (NIH)	T32 CA009614
National Childhood Cancer Registry – National Cancer Institute	24XS090, U01CA062491
National Center for Research Resources	UL1RR025011

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

Acceder al documento

10.1007/s00280-008-0845-0

Otros archivos y enlaces

Citar esto

@article{5ecb8d8422cb440bb008271e25d54242,

title = "Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors",

abstract = "Purpose: The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Methods: Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). Results: Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). Conclusion: RRM2 gene and protein expression varies by tumor type.",

keywords = "3-Aminopyridine-2-carboxaldehyde thiosemicarbazone, Automated quantitative immunohistochemistry (AQUA), Quantitative real time PCR, Ribonucleotide reductase, Triapine",

author = "Jill Kolesar and Wei Huang and Jens Eickhoff and Kristine Hahn and Dona Alberti and Steven Attia and William Schelman and Kyle Holen and Anne Traynor and Percy Ivy and George Wilding",

note = "Funding Information: Acknowledgments Supported by: U01CA062491 {\textquotedblleft}Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis{\textquotedblright} NCI; CTEP Translational Research Initiative Funding 24XS090, and 1ULRR025011. Clinical and Translational Science Award of the National Center for Research Resources, NIH; and NIH grant T32 CA009614. Physician Scientist Training in Cancer Medicine (Dr. Attia).",

year = "2009",

month = jun,

doi = "10.1007/s00280-008-0845-0",

language = "English",

volume = "64",

pages = "79--86",

number = "1",

}

TY - JOUR

T1 - Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

AU - Kolesar, Jill

AU - Huang, Wei

AU - Eickhoff, Jens

AU - Hahn, Kristine

AU - Alberti, Dona

AU - Attia, Steven

AU - Schelman, William

AU - Holen, Kyle

AU - Traynor, Anne

AU - Ivy, Percy

AU - Wilding, George

N1 - Funding Information: Acknowledgments Supported by: U01CA062491 “Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis” NCI; CTEP Translational Research Initiative Funding 24XS090, and 1ULRR025011. Clinical and Translational Science Award of the National Center for Research Resources, NIH; and NIH grant T32 CA009614. Physician Scientist Training in Cancer Medicine (Dr. Attia).

PY - 2009/6

Y1 - 2009/6

N2 - Purpose: The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Methods: Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). Results: Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). Conclusion: RRM2 gene and protein expression varies by tumor type.

AB - Purpose: The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Methods: Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). Results: Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). Conclusion: RRM2 gene and protein expression varies by tumor type.

KW - 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone

KW - Automated quantitative immunohistochemistry (AQUA)

KW - Quantitative real time PCR

KW - Ribonucleotide reductase

KW - Triapine

UR - https://www.scopus.com/pages/publications/67349119922

UR - https://www.scopus.com/pages/publications/67349119922#tab=citedBy

U2 - 10.1007/s00280-008-0845-0

DO - 10.1007/s00280-008-0845-0

M3 - Article

C2 - 18941749

AN - SCOPUS:67349119922

SN - 0344-5704

VL - 64

SP - 79

EP - 86

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 1

ER -

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Resumen

Nota bibliográfica

Financiación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto